Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 87Carcinoma, Non-Small-Cell Lung 78Multiple Myeloma 72Prostatic Neoplasms 66Neoplasms 47Lymphoma 43Leukemia, Myeloid, Acute 42Melanoma 38Neoplasm Metastasis 37Lymphoma, Non-Hodgkin 33Ovarian Neoplasms 32Lung Neoplasms 32Squamous Cell Carcinoma of Head and Neck 31Hematologic Neoplasms 29Leukemia, Lymphocytic, Chronic, B-Cell 28Colorectal Neoplasms 26Triple Negative Breast Neoplasms 23Hodgkin Disease 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Myelodysplastic Syndromes 21Sarcoma 20Fallopian Tube Neoplasms 20Pancreatic Neoplasms 19Carcinoma, Renal Cell 19Lymphoma, Follicular 17Leukemia 17Head and Neck Neoplasms 17Glioma 17Urinary Bladder Neoplasms 16Recurrence 16

Interventions

patritumab deruxtecan 1durvalumab 1Pemetrexed 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Non-Small Cell Lung Cancer Metastatic × 90 days × Clear all
NCT04163432 2026-05-19

STAGGER

University of Utah

Phase 2 Active not recruiting
43 enrolled 12 charts
Thoracic

Non-Small Cell Lung Cancer Metastatic

NCT04619004 2026-05-14

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Daiichi Sankyo

Phase 2 Active not recruiting
277 enrolled 16 charts
Thoracic

Non-Small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡